Team Consulting To Provide Seed Funding To Oval Medical
The investment is expected to enable Oval Medical to advance the development of its injection technology, including the production of new drug containers and prototype injection devices for
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.